New Compounds in PV

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.

The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.